IMRN
Immuron·NASDAQ
--
--(--)
--
--(--)
0.95 / 10
Underperform
Corporate fundamentals are rated poor at 0.9/10. Key concerns include an elevated Days Sales Outstanding (81.84 days, group 3) and modest revenue growth (48.63% YoY), which historically correlate with negative short-term returns. However, a solid Interest Coverage Ratio (42.48) provides some cushion, indicating the company can service debt adequately. Overall, the fundamental picture is one of subdued strength and operational challenges.
Analysis Checks(1/4)
Total operating revenue (YoY growth rate %)
Value48.63
Score1/3
Weight10.66%
1M Return-0.79%
Value48.63
Score1/3
Weight10.66%
1M Return-0.79%
Interest coverage ratio (EBIT / Interest expense) (%)
Value42.48
Score2/3
Weight14.56%
1M Return-1.11%
Value42.48
Score2/3
Weight14.56%
1M Return-1.11%
Days sales outstanding
Value81.84
Score0/3
Weight64.51%
1M Return-5.18%
Value81.84
Score0/3
Weight64.51%
1M Return-5.18%
Operating revenue (YoY growth rate %)
Value48.63
Score1/3
Weight10.27%
1M Return-0.76%
Value48.63
Score1/3
Weight10.27%
1M Return-0.76%
Total operating revenue (YoY growth rate %)
Value48.63
Score1/3
Weight10.66%
1M Return-0.79%
Value48.63
Score1/3
Weight10.66%
1M Return-0.79%
Days sales outstanding
Value81.84
Score0/3
Weight64.51%
1M Return-5.18%
Value81.84
Score0/3
Weight64.51%
1M Return-5.18%
Interest coverage ratio (EBIT / Interest expense) (%)
Value42.48
Score2/3
Weight14.56%
1M Return-1.11%
Value42.48
Score2/3
Weight14.56%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value48.63
Score1/3
Weight10.27%
1M Return-0.76%
Value48.63
Score1/3
Weight10.27%
1M Return-0.76%
Is IMRN undervalued or overvalued?
- IMRN scores 0.95/10 on fundamentals and holds a Premium valuation at present. Backed by its -50.21% ROE, -71.58% net margin, -1.92 P/E ratio, 1.24 P/B ratio, and 26.82% earnings growth, these metrics solidify its Underperform investment rating.
